The 2025 BioHealth Capital Region Crab Trap Competition will take place on September 24 at 2:00 PM during the Forum at US Pharmacopeia. Nearly 70 applications were received from around the world, and six innovative finalists will pitch for a prize package including $10,000 in cash, $25,000 in IT and cybersecurity services from InfoPathways, and $10,000 in CRO services from Noble Life Sciences and Accelevir. Don’t miss one of the week’s most exciting sessions.

Read more to see who the finalists are this year!

The 2025 BioHealth Capital Region Investment Conference takes place on September 25 at US Pharmacopeia in Rockville, MD, and it is the premier venue for connecting innovative biohealth startups with venture capital, strategic investors, and industry partners. With more than 150 participants already registered, including over 60 companies and 40 investors, this year’s conference will feature curated 1:1 partnering meetings, dynamic quick-pitch sessions, and targeted networking designed to spark collaboration and investment. Whether you are raising capital or scouting the next big opportunity, this is the place to be. Register today!

COLUMBIA, Md., (September 17, 2025) — TEDCO, Maryland’s economic engine for technology companies, announces the panel “AI Doesn’t Mean Automatic Investment: How to Separate Your Company From the AI Noise” to take place at the upcoming 2025 Entrepreneur Expo at The Hotel at the University of Maryland on October 21, 2025.

“Although many people believe that an AI-related company has an easier time attracting funds, this is not necessarily the case,” said Katherine Hill Ritchie, senior director, Venture Funds, TEDCO. “This panel will allow three experienced female entrepreneurs the chance to share their challenges in raising capital in a market filled with AI companies.”

CHARLOTTESVILLE, Va. (CBS19 NEWS) -- UVA’s Manning Institute of Biotechnology and AstraZeneca are teaming up to expand their research in modern medicine. 

The partnership was sparked after UVA named Dr. Mark Esser, a former vice president at AstraZeneca, the head of the Manning Institute. 

One of the active research projects between the two is working to find a treatment for C. Difficile, a bacteria that can cause colon damage. Esser says this partnership will help propel the outcomes of the institute’s research. 

“The mission of the institute is to transform...

Enjoy live music by The Impurities at the Wednesday evening reception on September 24 at USP. The band features USP team members showcasing their talent outside the lab, including Ron Piervincenzi, Ph.D., CEO, on guitar, Scott Bolgiano on guitar and backing vocals, John Daly on drums, Tim Greiner on lead vocals and harmonica, Alyssa Lang on vocals and saxophone, and Horacio Pappa on keyboards. It is a fun way to connect with peers after a full day of sessions.— register today for the Forum:

GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29 million (USD). The orders span several product offerings within Emergent’s medical countermeasures (MCM) business, including...

INDIANAPOLIS, Sept. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new site will be the company's first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio.

Earlier this year, at a press conference in Washington, D.C., Lilly announced plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. The planned Virginia facility is the first...

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply TEMBEXA® (brincidofovir) oral suspension. This follows the U.S. Food and Drug Administration’s (FDA) recent approval of the manufacturing scale-up of TEMBEXA® oral suspension. Oral suspension formulation is an important option for patients who may have trouble swallowing due to age or medical status.

In a new National Institutes of Health-funded research report, scientists at Johns Hopkins Medicine say they have identified a potential target for drugs that could dial up or down the activity of certain brain proteins in efforts to treat psychiatric disorders, such as anxiety and schizophrenia, and a neurological condition that affects movement.

The proteins, called delta-type ionotropic glutamate receptors, or GluDs, have long been understood to play a major role in signaling between neurons. Mutations in GluD proteins are thought to drive psychiatric conditions, including anxiety and schizophrenia, the scientists say. Yet, scientists had few clues as to how GluDs function, hampering the ability to find treatments to regulate them.